Abivax S.A. Stock
Price
Target price
€14.84
€14.84
0.680%
0.1
0.680%
-
26.04.24 / Tradegate
WKN: A14UQC / Name: Abivax / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Financial data and news for Abivax
sharewise wants to provide you with the best news and tools for Abivax, so we directly link to the best financial data sources.
Financials
News
EQS-News: Abivax publishes financial reports with the French and U.S. securities regulatory agencies
EQS-News: Abivax publishes financial reports with the French and U.S. securities regulatory agencies
EQS-News: Abivax reports 2023 financial results and operational update
EQS-News: Abivax reports 2023 financial results and operational update
EQS-News: Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO)
EQS-News: Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO)
EQS-News: Abivax appoints Ana Sharma as Vice President, Global Head of Quality
EQS-News: Abivax appoints Ana Sharma as Vice President, Global Head of Quality
EQS-News: Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease
EQS-News: Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease
EQS-News: Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024
EQS-News: Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024
EQS-News: Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months
EQS-News: Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months
EQS-News: Abivax 2024 Financial Communication Calendar
EQS-News: Abivax 2024 Financial Communication Calendar
EQS-News: Abivax announces the resumption of its liquidity contract
EQS-News: Abivax announces the resumption of its liquidity contract
EQS-News: Abivax to participate in the Piper Sandler 35th Annual Healthcare Conference
EQS-News: Abivax to participate in the Piper Sandler 35th Annual Healthcare Conference